{"schema_version":"secwatch.filing_event.v1","accession":"0001549595-23-000053","form_type":"8-K","ticker":"NRIX","cik":"0001549595","company_name":"Nurix Therapeutics, Inc.","filed_at":"2023-11-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.477569+00:00","generated_at":"2026-06-09T02:33:22.477237+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"FDA places partial clinical hold on Nurix's NX-2127 Phase 1 trial; enrollment paused","bullets":["FDA partial clinical hold on U.S. Phase 1 study NX-2127-001 for B-cell malignancies; screening and enrollment paused.","Patients currently enrolled who derive clinical benefit may continue treatment per ongoing protocol.","Hold follows Nurix's communication to FDA of intention to transition to an improved manufacturing process.","Nurix's other drug programs are not affected by the NX-2127 manufacturing process improvement."],"urls":{"canonical":"https://secwatch.observer/filing/0001549595-23-000053","json":"https://secwatch.observer/filing/0001549595-23-000053.json","markdown":"https://secwatch.observer/filing/0001549595-23-000053.md","text":"https://secwatch.observer/filing/0001549595-23-000053.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1549595/000154959523000053/0001549595-23-000053-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1549595/000154959523000053/nrix-20231101.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T02:33:22.477237+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}